Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia
Status:
Completed
Trial end date:
2017-12-08
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled exploratory trial to investigate
efficacy and safety of food supplement IGN-ES001 in patients with chronic widespread pain
(CWP) with or without fibromyalgia (FM).
Phase:
N/A
Details
Lead Sponsor:
IgNova GmbH
Collaborators:
CenTrial GmbH idv Data Analysis and Study Planning Klinar CRO Pharmasolutions4U SCOPE International AG